Loading…
Loading grant details…
| Funder | Swedish Research Council |
|---|---|
| Recipient Organization | Karolinska Institutet |
| Country | Sweden |
| Start Date | Jan 01, 2025 |
| End Date | Dec 31, 2028 |
| Duration | 1,460 days |
| Number of Grantees | 5 |
| Roles | Co-Investigator; Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2024-03214_VR |
Background: Despite aggressive surgery coupled with radiation/chemoradiation, the 5-year overall survival rate of oral squamous cell carcinoma (OSCC) has stagnated at 50% for decades.
While cancer immunotherapy holds promise, OSCC patients typically experience only modest enhancements compared to other cancer types. Advancing immunotherapies requires a deeper understanding of cancer immunity mechanisms.
Insights into neutrophil immunity, with their potential to influence pro- and anti-cancer responses, particularly within tumor-draining lymph nodes (TDLNs), remain limited.Goal: To dissect the immunomodulatory roles of neutrophils in TDLNs across various stages of OSCC and characterize their potential as facilitators of metastasis within these nodes.
The project has 4 aims that synergistically build upon one another.Methods: Several techniques, including single-cell sequencing, flow cytometry, and spatial transcriptomics, will be deployed to characterize fresh samples of OSCC tumors, TDLNs, and non-TDLNs, alongside lymph nodes from non-cancer patients.
Boyden chambers, in conjunction with an orthotopic xenograft model, will be utilized to investigate the involvement of tumor-associated neutrophils in cancer dissemination to TDLNs.Clinical Implications: A successful outcome has the potential to catalyze the development of novel strategies aimed at bolstering immune responses against cancer, thereby potentially enhancing the effectiveness of existing cancer immunotherapies.
Karolinska Institutet
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant